ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron

Immunoprecise Antibodies Ltd IPA has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail.

  • The data demonstrated robust neutralizing potency of the antibody cocktail towards the omicron variant (B.1.1.529) in in vitro pseudovirus assays. 
  • The Company believes that it possesses the only first-generation cocktail therapy against SARS-CoV-2 (first publicly announced 2020) that has been demonstrated to retain efficacy against every variant of concern to date. 
  • PolyTope TATX-03, a cocktail of four monoclonal antibodies, can engage multiple modes of action, facilitated by simultaneously targeting various non-overlapping epitopes on the spike trimer.
  • The Company expects that, upon completion of its ongoing studies, the data will enable the Company to file an Investigational New Drug (IND) application.
  • Immunoprecise announced a manufacturing agreement with ChemPartner Biologics Co Ltd in December for IPA's PolyTope TATX-03 Therapy.
  • Price Action: IPA shares traded 10.90% higher at $6.40 premarket on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!